KORU Medical Systems Appoints Josh Bennett VP Global Commercialization
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical”) today announced the appointment of Josh Bennett to the newly created position of Vice President Global Commercialization. Mr. Bennett brings 20 years of healthcare management and consulting experience to KORU Medical. He will be responsible for creating and executing initiatives designed to accelerate KORU Medical’s growth, with a focus on business development and product commercialization. Mr. Bennett will report directly to Don Pettigrew, President and CEO of KORU Medical.
Mr. Bennett’s experience spans healthcare product categories, care settings, and end markets, including medical devices / technology, pharmaceuticals, biologics, acute care, and home care. He has been responsible for growth in both U.S. and international markets.
He joins KORU Medical from Salter Labs, a global anesthesia and respiratory medical device manufacturer, where he served as Vice President Sales, Marketing, and Business Development beginning in 2012. Salter Labs merged with SunMed in 2019. Prior to this, he was with Baxter Healthcare, a Fortune 500 diversified global pharmaceutical and device manufacturer. At Baxter he focused on pharmaceuticals and biologics, with an emphasis on product and market development addressing nutrition, hydration, and hemophilia. Mr. Bennett began his career at PwC Consulting (now IBM Global Business Services).
Mr. Bennett received his MBA from the Kellogg School of Management at Northwestern University, where he was a Siebel Scholar and recipient of the Richard M. Clewett Award, and his BBA from Northwood University.
“Josh brings knowledge, experience and industry contacts to KORU Medical at a time of expanding opportunity,” said Don Pettigrew. “He has a broad and proven record of building marketing programs and creating new sales channels domestically and internationally that deliver strong results. We believe that Josh’s skills align well with our goals of identifying new and adjacent market opportunities, expanding the therapeutic and pharmaceutical applications of our Freedom60 integrated infusion system, and leveraging what we view as significant advantages of self-administered at-home infusion therapy.”
“I am excited to join KORU Medical at a time of significant growth and market capture potential,” said Mr. Bennett. “I look forward to collaborating with the team to expand KORU Medical’s patient-focused platform and advance the company’s long-term growth strategy.”
About KORU Medical
KORU Medical manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information about the Company, please visit www.korumedical.com.
This press release may contain forward-looking statements that involve risks and uncertainties, identified by words such as “will”, “believe” and “view”. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, as amended, and our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, which are on file with the SEC and are available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
The Equity Group Inc.
Senior Vice President
Kalle Ahl, CFA
Source: KORU Medical Systems
Released July 8, 2020